SciVision Biotech Inc
TWSE:1786
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (28.7), the stock would be worth NT$9.96 (83% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 165.7 | NT$57.5 |
0%
|
| 3-Year Average | 28.7 | NT$9.96 |
-83%
|
| 5-Year Average | 29.2 | NT$10.12 |
-82%
|
| Industry Average | 24.4 | NT$8.46 |
-85%
|
| Country Average | 20.4 | NT$7.06 |
-88%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| TW |
|
SciVision Biotech Inc
TWSE:1786
|
4.3B TWD | 165.7 | 26.5 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY | 47.1 | 39.3 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.4B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.2B CHF | 23.9 | 36.2 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
89.7B DKK | 20.5 | 22.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.6B USD | 23.3 | 30.6 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -73.3 | -36.5 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 24.1 | 31.2 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
38B CNY | 31.8 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.8B CNY | -32 | 22.2 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
875B JPY | 24.6 | 49.5 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 13.5 |
| Median | 20.4 |
| 70th Percentile | 30.6 |
| Max | 2 037.1 |
Other Multiples
SciVision Biotech Inc
Glance View
SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.
